News for 'Pharma'

Excise policy: ED attaches assets worth Rs 115 cr of 2 approvers

Excise policy: ED attaches assets worth Rs 115 cr of 2 approvers

Rediff.com4 Jun 2024

The agency made the disclosure in a chargesheet filed by it on May 10 against former Telangana chief minister and Bharat Rashtra Samithi leader K Chandrashekar Rao's MLC daughter K Kavitha and four others.

After showing signs of recovery, pharma sales dip in July

After showing signs of recovery, pharma sales dip in July

Rediff.com11 Aug 2020

Growth has been under pressure since the lockdowns related to Covid-19 started and fresh prescription generations slowed.

Investors' wealth up by Rs 11 lk cr in 5 days

Investors' wealth up by Rs 11 lk cr in 5 days

Rediff.com25 Apr 2024

The market capitalisation of BSE-listed companies jumped to a lifetime peak of Rs 404.18 lakh crore on Thursday helped by a five-day rally in benchmark indices, making investors richer by Rs 11.29 lakh crore. Recovering after a sell-off in early trade, the 30-share BSE Sensex climbed 486.50 points or 0.66 per cent to settle at 74,339.44 on Thursday. During the day, it surged 718.31 points or 0.97 per cent to 74,571.25.

Tapping into India's talent, GCCs eye revenue goldmine

Tapping into India's talent, GCCs eye revenue goldmine

Rediff.com28 Mar 2024

Global capability centres (GCCs) are increasingly looking to tap into revenue opportunities from the Indian market, which is already a critical talent hub. While capturing the potential of the Indian market has been in the works over the past few years, it's only of late that companies are gaining momentum. India is home to more than 1,580 GCCs, with a total market size of $46 billion and growing at a compound annual growth rate (CAGR) of 11.4 per cent, according to a Nasscom-Zinnov report.

Stock markets rebound; Sensex closes up 111 points

Stock markets rebound; Sensex closes up 111 points

Rediff.com13 May 2024

From the Sensex basket, Asian Paints, Sun Pharma, HDFC Bank, Tata Consultancy Services, Axis Bank, Tata Steel, JSW Steel, Larsen & Toubro, ICICI Bank and Power Grid were the major gainers. Tata Motors dropped over 8 per cent despite reporting over three-fold jump in consolidated net profit at Rs 17,528.59 crore for the fourth quarter ended March 31, 2024. NTPC, Bharti Airtel, Titan, State Bank of India and Nestle were the other major laggards.

Almost fell asleep: Biden on debate debacle against Trump

Almost fell asleep: Biden on debate debacle against Trump

Rediff.com3 Jul 2024

The White House acknowledged that Biden did not have a "great (debate) night,", but asserted that he knew how to get things done and is ready to run the country for the next four years.

And Radhika-Anant Are Married...

And Radhika-Anant Are Married...

Rediff.com13 Jul 2024

The list of guests included celebrities from across the globe, politicians, the who's who of Hindi and south Indian cinema world and almost all the top cricketers of the country.

USFDA warns Aurobindo Pharma

USFDA warns Aurobindo Pharma

Rediff.com23 May 2011

Company had earlier received an import alert in February this year from the US Food and Drug Administration.

BSE Sensex: 10 biggest single-day falls

BSE Sensex: 10 biggest single-day falls

Rediff.com4 Jun 2024

Among the 30 Sensex companies, Larsen & Toubro, Power Grid, NTPC, State Bank of India, Reliance Industries and HDFC Bank were the biggest laggards. Sun Pharma and Nestle were the only gainers.

Revised Schedule M elicits mixed response

Revised Schedule M elicits mixed response

Rediff.com8 Jan 2024

A notification of the revised Schedule M rules by the Ministry of Health and Family Welfare has elicited mixed responses from the pharma sector and industry observers. While the industry has welcomed the revision of rules, several analysts said that implementation and compliance can become a challenge for smaller pharmaceutical companies. The Schedule M of the Drugs and Cosmetics Rules specifies the good manufacturing practices (GMPs), which aim to ensure quality of drugs made in the country.

Govt nearly doubles PLI scheme share of five key industry segments

Govt nearly doubles PLI scheme share of five key industry segments

Rediff.com12 Feb 2024

In a big push to the production-linked incentive (PLI) scheme, the government has nearly doubled (increase of 81 per cent) the allocation in five key industry segments from Rs 8,405 crore in the Revised Estimate of FY24 to Rs 15,198 crore in the Interim Budget for FY25. The segments cover over eight PLI schemes, including mobile phones, IT hardware, pharma (PLIs for medical devices, intermediates and pharmaceuticals), food processing, telecom hardware and, auto and auto components. In FY24, DPIIT officials, however, said that the disbursements would be much higher at around Rs 11,000 crore than what has been budgeted for the year.

Sun Pharma acquires US-based Pharmalucence

Sun Pharma acquires US-based Pharmalucence

Rediff.com16 Jul 2014

Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.

Markets ride on banking, IT shares to close at new highs

Markets ride on banking, IT shares to close at new highs

Rediff.com6 Mar 2024

Among the Sensex firms, Kotak Mahindra Bank, Axis Bank, Bharti Airtel, Sun Pharma, HCL Technologies, Mahindra & Mahindra, Titan and Tata Consultancy Services were the biggest gainers. UltraTech Cement, NTPC, Maruti, JSW Steel, Power Grid and Tata Motors were among the laggards.

In absence of black swans, markets may rise further

In absence of black swans, markets may rise further

Rediff.com18 Mar 2024

Since March 2020, when the Nifty50 plummeted to 7,511 following the announcement of a nationwide lockdown, the stock market has been on an upward trajectory. Over the next four years, the major market index has delivered a remarkable compounded annual growth rate (CAGR) of over 31.5 per cent. In the past year alone, the Nifty50 has gained by 27 per cent, hitting a succession of record highs.

Indian pharma's Trump fears

Indian pharma's Trump fears

Rediff.com1 Feb 2017

Industry fears tougher US stance on IP after President Donald Trump asserted that foreign countries must pay a fair share for drug development costs. Aneesh Phadnis reports.

Sensex ends down 354 points; RIL, Airtel drag

Sensex ends down 354 points; RIL, Airtel drag

Rediff.com5 Feb 2024

Among the Sensex firms, Bajaj Finance, Bharti Airtel, Maruti, Bajaj Finserv, HCL Technologies, Titan, Hindustan Unilever, JSW Steel, UltraTech Cement, State Bank of India and Reliance Industries were the major laggards.

Why Japan is betting big on Indian pharma cos

Why Japan is betting big on Indian pharma cos

Rediff.com26 Jan 2017

One reason Japan is betting highly on Indian pharma is that these companies have strong cash flows, low leverage and high debt capacity for medium to large sized acquisitions.

Ambani beats Adani to remain India's richest; ranks 9th in global list

Ambani beats Adani to remain India's richest; ranks 9th in global list

Rediff.com3 Apr 2024

Oil-to-telecom conglomerate Reliance Industries Ltd head Mukesh Ambani continues to be the richest Indian and has now broken into the world's top 10 wealthiest persons in the latest Forbes 2024 Billionaire List. Ambani, 66, is ranked 9th on the list with a wealth of $116 billion, up from $83.4 billion in the 2023 ranking, according to Forbes. Gautam Adani is the second richest Indian and is ranked at No.17 on the global list.

Financial, pharma stocks give Sensex a 359-point boost

Financial, pharma stocks give Sensex a 359-point boost

Rediff.com10 Jun 2021

On the Sensex chart, Bajaj Finance, Bajaj FinServ, SBI, IndusInd Bank, Dr Reddy's, Tech Mahindra, ITC and Kotak Bank were the prominent gainers - rising up to 7.29 per cent. NSE Nifty climbed 102.40 points to end at 15,737.75.

Sensex climbs 167 points on buying in bank shares, Reliance

Sensex climbs 167 points on buying in bank shares, Reliance

Rediff.com9 Feb 2024

Benchmark Sensex rebounded by 167 points in a volatile trade on Friday amid buying in ICICI Bank, State Bank of India and Reliance Industries. The 30-share BSE Sensex climbed 167.06 points or 0.23 per cent to settle at 71,595.49. During the day, it hit a high of 71,676.49 and a low of 71,200.31.

Stock markets close lower on fag-end selling in banking, IT shares

Stock markets close lower on fag-end selling in banking, IT shares

Rediff.com30 Apr 2024

From the Sensex basket, Tech Mahindra, Tata Steel, JSW Steel, HCL Technologies, Tata Consultancy Services, Larsen & Toubro and Kotak Mahindra Bank were the biggest laggards. Mahindra & Mahindra, Power Grid, Bajaj Finance, IndusInd Bank and Maruti were the major gainers.

Sensex gains 268 points on fag-end buying

Sensex gains 268 points on fag-end buying

Rediff.com14 Feb 2024

State Bank of India was the biggest gainer in the Sensex pack, rising 4.24 per cent, followed by Tata Steel, Axis Bank, Maruti, NTPC, PowerGrid, ITC and Nestle India. Reliance jumped 1.15 per cent to end at Rs 2,962.60 apiece on BSE.

Mcap of BSE-listed companies soar to all-time high of Rs 406.52 lakh cr

Mcap of BSE-listed companies soar to all-time high of Rs 406.52 lakh cr

Rediff.com29 Apr 2024

The market capitalisation of BSE-listed companies soared to an all-time high of Rs 406.52 lakh crore on Monday thanks to a rally in equities where the BSE Sensex climbed over 1 per cent. The 30-share BSE Sensex rallied 941.12 points or 1.28 per cent to finish at 74,671.28. During the day, it zoomed 990.99 points or 1.34 per cent to 74,721.15.

How companies show electoral donations in annual reports

How companies show electoral donations in annual reports

Rediff.com20 Mar 2024

A reading of the reports suggests that there is no standard practice for reporting political contributions and it is left to the company's discretion to report them as they find fit.

Even MBAs Find It Tough To Get Jobs

Even MBAs Find It Tough To Get Jobs

Rediff.com1 Jul 2024

'Corporations that were recruiting 15 or 20 [students] have reduced the number to two or three.'

Electoral bonds: Vast majority of parties including BSP, Left got no funding

Electoral bonds: Vast majority of parties including BSP, Left got no funding

Rediff.com17 Mar 2024

The National People's Party, which rules Meghalaya, is another national party which received no donations through electoral bonds.

Healthcare sector most violative of advertisement rules, says Asci report

Healthcare sector most violative of advertisement rules, says Asci report

Rediff.com23 May 2024

Maximum cases of advertisement norms violations were reported from the healthcare sector during 2023-24, followed by illegal offshore betting and personal care categories, according to the Advertising Standards Council of India's (Asci's) Annual Complaints Report released on Wednesday. The healthcare sector accounted for a maximum 19 per cent or 1,569 of 8,229 advertisements scrutinised by Asci during the year. Illegal offshore betting accounted for 17 per cent, while the share of personal care advertisements was 13 per cent.

Daiichi Sankyo to offload stake in Sun Pharma

Daiichi Sankyo to offload stake in Sun Pharma

Rediff.com20 Apr 2015

Daiichi won't remain a major shareholder in Sun Pharma.

Pharma stocks on a booster dose

Pharma stocks on a booster dose

Rediff.com1 Mar 2014

Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally

7 Indian pharma players race to develop COVID-19 vaccine

7 Indian pharma players race to develop COVID-19 vaccine

Rediff.com19 Jul 2020

Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.

Pharma sector can be a good bet

Pharma sector can be a good bet

Rediff.com17 Nov 2015

Analysts say those taking exposure through stocks could look at firms focused on domestic business

Campus Placements At IITs Getting Tough

Campus Placements At IITs Getting Tough

Rediff.com8 Jul 2024

Nearly 40 per cent of IITians sitting for placements in 2024 are yet to receive job offers, showing a doubling of the 'unplaced' in the last three years from 19 per cent in 2021-2022 to 38 per cent in 2023-2024.

'Tax Relief For Middle Class Will Boost Markets'

'Tax Relief For Middle Class Will Boost Markets'

Rediff.com1 Jul 2024

'Like every Budget, this time, too, there is chatter around tinkering with the long-term capital gains tax.' 'Investors may not want to jump into the markets until there is clarity on this front.'

'Investor migration in IT and pharma will stay for a while'

'Investor migration in IT and pharma will stay for a while'

Rediff.com23 Dec 2020

'Quality of management, corporate governance, allocation of capital, full disclosures should form the basis to decide investing in a particular stock.'

Sensex, Nifty end flat in volatile trade

Sensex, Nifty end flat in volatile trade

Rediff.com23 Feb 2024

Among Sensex shares, HCLTech, Asian Paints, Maruti, JSW Steel, TCS, SBI, ITC and Bharti Airtel were the major losers. On the other hand, Bajaj Finserv, Mahindra & Mahindra, Titan, L&T and Wipro were the major gainers.

Gas leak at pharma plant in Vizag leaves 2 dead

Gas leak at pharma plant in Vizag leaves 2 dead

Rediff.com30 Jun 2020

The leakage of benzimidazole gas occurred at Sainor Life Sciences Pvt Ltd in Visakhapatnam on Monday night.

Markets end flat in volatile trade ahead of RBI's rate decision

Markets end flat in volatile trade ahead of RBI's rate decision

Rediff.com7 Feb 2024

Among the Sensex firms, State Bank of India rose the most by 3.78 per cent after the bank announced the acquisition of SBI CAPS subsidiary for Rs 708.07 crore. Nestle India gained 1.68 per cent after it reported around 9 per cent growth in sales. JSW Steel, Bajaj Finance, Axis Bank and Asian Paints were among the gainers.

At Rs 35 a pill, Sun Pharma's FluGuard is the cheapest favipiravir drug

At Rs 35 a pill, Sun Pharma's FluGuard is the cheapest favipiravir drug

Rediff.com5 Aug 2020

Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate Covid-19 disease.

Why Daiichi's exit is good for Sun Pharma

Why Daiichi's exit is good for Sun Pharma

Rediff.com22 Apr 2015

But splitting management bandwidth by investing in non-core businesses will not be appreciated by the market in the long run.